A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)

Trial Profile

A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Verubecestat (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Registrational; Therapeutic Use
  • Acronyms APECS
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Feb 2017 Planned number of patients changed from 1500 to 1350.
    • 14 Feb 2017 According to the Merck AG media release, results from this study are expected in February 2019.
    • 22 Nov 2016 Planned primary completion date changed from 1 May 2019 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top